vimarsana.com
Home
Live Updates
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis : comparemela.com
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
- 70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37% Achieved ALP Normalization at 12 Months -
- Reduction in Patient-Reported Pruritus was...
Related Keywords
United Kingdom ,
Washington ,
United States ,
Foster City ,
California ,
Merdad Parsey ,
Gilead Sciences In Liver Disease ,
Gilead Sciences Inc ,
Regulatory Agency ,
Nasdaq ,
Gilead Company ,
Exchange Commission ,
Cymabay Therapeutics Inc ,
Drug Administration ,
University Of Miami ,
European Medicines Agency ,
Gilead Sciences ,
Cymabay Therapeutics ,
Presidential Plenary ,
Digestive Disease ,
Cynthia Levy ,
Chief Medical Officer ,
New Drug Application ,
Child Pugh ,
United Kingdom Medicines ,
Primary Biliary Cholangitis ,
Interim Results ,
Bay Therapeutics ,
Private Securities Litigation Reform Act ,
Quarterly Report ,
Liver Disease ,
comparemela.com © 2020. All Rights Reserved.